Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C25H34O6 |
| Molecular Weight | 430.5348 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(CCC)O2)C(=O)CO
InChI
InChIKey=VOVIALXJUBGFJZ-KWVAZRHASA-N
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
| Molecular Formula | C25H34O6 |
| Molecular Weight | 430.5348 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01222
https://www.drugs.com/cdi/budesonide-extended-release-tablets.html
http://www.wikidoc.org/index.php/Budesonide_(inhalation)#Adverse_Reactions
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01222
https://www.drugs.com/cdi/budesonide-extended-release-tablets.html
http://www.wikidoc.org/index.php/Budesonide_(inhalation)#Adverse_Reactions
Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, allergic rhinitis and ulcerative colitis. The precise mechanism of corticosteroid actions on inflammation in asthma is not well known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic- and non-allergic-mediated inflammation. The anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Commonly reported side effects of budesonide include: acne vulgaris, moon face, and bruise. Other side effects include: ankle edema, hirsutism, weakness, arthralgia, nausea, and rhinitis. Ketoconazole, a potent inhibitor of cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4), the main metabolic enzyme for corticosteroids, increased plasma levels of orally ingested budesonide.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3811967
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL340 |
|||
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB01222 |
1.32 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PULMICORT RESPULES Approved UsePULMICORT FLEXHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older. (1.1) Important Limitations: • Not indicated for the relief of acute bronchospasm. (1.1) 1.1 Treatment of Asthma PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in patients six years of age or older. Important Limitations of Use: PULMICORT FLEXHALER is NOT indicated for the relief of acute bronchospasm. Launch Date2000 |
|||
| Primary | UCERIS Approved UseUCERIS rectal foam is indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge. Launch Date2013 |
|||
| Palliative | RHINOCORT ALLERGY Approved UseIt is indicated for the treatment of nasal symptoms of seasonal or perennial allergic rhinitis in adults and children Launch Date2015 |
|||
| Primary | ENTOCORT EC Approved UseENTOCORT EC is indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. Launch Date2001 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015-06 |
|
| Thiobenzothiazole-modified Hydrocortisones Display Anti-inflammatory Activity with Reduced Impact on Islet β-Cell Function. | 2015-05-22 |
|
| Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015-01-05 |
|
| Potentiated interaction between ineffective doses of budesonide and formoterol to control the inhaled cadmium-induced up-regulation of metalloproteinases and acute pulmonary inflammation in rats. | 2014 |
|
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | 2013-12 |
|
| Mechanisms of action of hormone-sensitive lipase in mouse Leydig cells: its role in the regulation of the steroidogenic acute regulatory protein. | 2013-03-22 |
|
| Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study. | 2012-07-01 |
|
| Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. | 2012-05-01 |
|
| Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. | 2012-03 |
|
| Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway. | 2011-12 |
|
| Some OH-PCBs are more potent inhibitors of aromatase activity and (anti-) glucocorticoids than non-dioxin like (NDL)-PCBs and MeSO₂-PCBs. | 2011-10-10 |
|
| Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. | 2011-10-01 |
|
| Hyalinization of the pyloric stomach in CD-1 mice following oral (dietary) administration of the corticosteroid agonists mometasone furoate, budesonide, and flunisolide. | 2011-10 |
|
| Contact sensitization in very young children. | 2011-10 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. | 2011-06 |
|
| Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids. | 2011-05-30 |
|
| The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices. | 2011-02 |
|
| Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. | 2010-07 |
|
| Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea. | 2010-04 |
|
| Recurrent spontaneous gastrointestinal graft-versus-host disease in autologous hematopoietic stem cell transplantation. | 2010-02 |
|
| Mass casualties from acute inhalation of chlorine gas. | 2009-12 |
|
| Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma. | 2009-12 |
|
| Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. | 2009-07 |
|
| Management of Crohn's disease in adults. | 2009-02 |
|
| Contact allergy to topical corticosteroids--results from the IVDK and epidemiological risk assessment. | 2009-01 |
|
| Oxidative stress modulates theophylline effects on steroid responsiveness. | 2008-12-19 |
|
| A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions. | 2008-10 |
|
| Tolerance and rebound with zafirlukast in patients with persistent asthma. | 2008-05-19 |
|
| Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism. | 2008-04 |
|
| The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. | 2007-11 |
|
| [Effects of beclomethasone dipropionate and budesonide on interleukin-13 induced cytokine release, proliferation and differentiation of the human lung fibroblasts]. | 2007-08 |
|
| Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. | 2007-03-01 |
|
| Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT). | 2006-12 |
|
| Reversible dementia with parkinsonian features associated with budesonide use. | 2006-08-22 |
|
| Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids. | 1997-12-01 |
|
| [Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide]. | 1997-06-15 |
|
| The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. | 1997-06 |
|
| Severe hypokalemia after budesonide treatment for Crohn's disease. | 1997-03 |
|
| Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. | 1996-12 |
|
| Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge. | 1995-08 |
|
| Evaluation of the inhibitory effects of budesonide on the mitogen-induced or the allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. | 1995-07 |
|
| Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. | 1995-04 |
|
| Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. | 1995-01 |
|
| The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells. | 1994-08-01 |
|
| Contact sensitivity and cross-reactivity of budesonide. | 1993-04 |
|
| Contact allergies to topical corticosteroids. | 1993-03 |
|
| [Contact allergy to topical glucocorticoids]. | 1993-02 |
|
| Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. | 1983-11 |
|
| Methodological aspects on clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma. | 1982 |
Sample Use Guides
200 to 400 ug twice daily. If previous therapy was Oral Corticosteroids - 400 to 800 ug twice daily rectal foam: 1 metered dose administered twice daily for 2 weeks followed by 1 metered dose (rectal foam contains 2 mg budesonide per metered dose). Administered once daily for 4 weeks.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9374115
Increased hemopoietic activity in naive bone marrow, stimulated by serum obtained 24 h after allergen inhalation from sensitized dogs, can be prevented by prior incubation of the marrow with budesonide (10−7 M).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 06:37:07 GMT 2025
by
admin
on
Wed Apr 02 06:37:07 GMT 2025
|
| Record UNII |
Q3OKS62Q6X
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR03BA02
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ATC |
R03BA02
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
673818
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
VYLAER SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
634418
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ATC |
R03AK07
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
394613
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
305710
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ATC |
R03AK12
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
NDF-RT |
N0000175576
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
DUORESP SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
25.1
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ATC |
D07AC09
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
227406
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ATC |
A07EA06
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
LIVERTOX |
NBK548351
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
FDA ORPHAN DRUG |
670118
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-VATC |
QR01AD05
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
BIRESP ( AUTHORIZED: ASTHMA, PLUMONARY DISEASE, CRONIC OBSTRUCTIVE)
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/13/1181
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
LABAZENIT (REFUSED: ASTHMA)
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
NDF-RT |
N0000175450
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ATC |
R01AD05
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
28
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-VATC |
QR03AK07
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-VATC |
QA07EA06
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
BUDESONIDA (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
||
|
WHO-VATC |
QD07AC09
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB05955MIG
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
4145
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
Q3OKS62Q6X
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
C1027
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
Budesonide
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
5281004
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
257-139-7
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
DB01222
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
Q3OKS62Q6X
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
19831
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | RxNorm | ||
|
D019819
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
3207
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
7434
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
1078201
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
100000091309
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
419
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
51333-22-3
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
m2746
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | Merck Index | ||
|
757788
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
DTXSID8020202
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
BUDESONIDE
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY | |||
|
CHEMBL1370
Created by
admin on Wed Apr 02 06:37:07 GMT 2025 , Edited by admin on Wed Apr 02 06:37:07 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
EXCRETED UNCHANGED |
No unchanged budesonide is detected in urine.
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BINDER->LIGAND |
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
BINDING
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
In vitro mediator: CYP3A4
|
||
|
METABOLITE -> PARENT |
Catalyzed by two enzymes, the 4-ene-5.BETA.-reductase and the 4-ene-5.ALPHA.-reductase
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
In vitro mediator: CYP3A4
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
Catalyzed by two enzymes, the 4-ene-5.BETA.-reductase and the 4-ene-5.ALPHA.-reductase
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
Catalyzed by two enzymes, the 4-ene-5.BETA.-reductase and the 4-ene-5.ALPHA.-reductase. The second stage utilizes the enzymes 3.ALPHA.- and, to a much lesser extent, 3.BETA.-hydroxysteroid dehydrogenases
MINOR
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
Limit includes both epimers
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
This impurity is to be reported under total unspecified impurities. Do not report it under total specified impurities.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Limit includes both epimers
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
This impurity is to be reported under total unspecified impurities. Do not report it under total specified impurities.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Limit includes both epimers.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
|
IMPURITY -> PARENT |
Implied to be a potential or real impurity
|
||
|
IMPURITY -> PARENT |
Limit includes both epimers
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|